Toll Free: 1-888-928-9744

Botulism - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Botulism - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Botulism - Pipeline Review, H1 2016', provides an overview of the Botulism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Botulism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Botulism and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Botulism - The report reviews pipeline therapeutics for Botulism by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Botulism therapeutics and enlists all their major and minor projects - The report assesses Botulism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Botulism Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Botulism - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Botulism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Botulism Overview 7 Therapeutics Development 8 Pipeline Products for Botulism - Overview 8 Pipeline Products for Botulism - Comparative Analysis 9 Botulism - Therapeutics under Development by Companies 10 Botulism - Therapeutics under Investigation by Universities/Institutes 11 Botulism - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Botulism - Products under Development by Companies 14 Botulism - Products under Investigation by Universities/Institutes 15 Botulism - Companies Involved in Therapeutics Development 16 Hawaii Biotech, Inc. 16 Medytox Solutions, Inc. 17 Microbiotix, Inc. 18 Molecular Targeting Technologies, Inc. 19 XOMA Corporation 20 Botulism - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 BoNT/A HcR4 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 botulinum vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 botulism [serotypes A, B, C, D, E] vaccine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 botulism [serotypes A, B] vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 OSX-400 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 OSX-400 Backups - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Polyclonal Antibody for Botulism - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules for Botulism - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 XOMA-3AB - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Botulism - Recent Pipeline Updates 44 Botulism - Dormant Projects 45 Botulism - Discontinued Products 46 Botulism - Product Development Milestones 47 Featured News & Press Releases 47 May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for Botulism, H1 2016 8 Number of Products under Development for Botulism - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Botulism - Pipeline by Hawaii Biotech, Inc., H1 2016 16 Botulism - Pipeline by Medytox Solutions, Inc., H1 2016 17 Botulism - Pipeline by Microbiotix, Inc., H1 2016 18 Botulism - Pipeline by Molecular Targeting Technologies, Inc., H1 2016 19 Botulism - Pipeline by XOMA Corporation, H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Botulism Therapeutics - Recent Pipeline Updates, H1 2016 44 Botulism - Dormant Projects, H1 2016 45 Botulism - Discontinued Products, H1 2016 46



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify